Nine isolates of Klebsiella pneumoniae, obtained from one colonized and eight bacteraemic patients on a paediatric ward, were shown to be identical by PFGE, indicating an outbreak. Screening for extended-spectrum -lactamase (ESBL) production using the double-disc synergy test, Etest for ESBLs and agar diffusion tests indicated ESBL production. The isolates showed reduced susceptibility to cefotaxime but not to other third-generation cephalosporins. Molecular studies revealed production of TEM-1 and SHV-1 but no ESBLs were identified. Deficiency in expression of an outer membrane protein (OmpK35) was also observed. These observations led us to postulate that the extremely low level of OmpK35 expression and the co-existence of TEM-1 and SHV-1 resulted in an increased MIC of cefotaxime and the false designation of the isolates as ESBL producers. All the infected infants were treated with either third-generation cephalosporins alone or multiple antibiotics including a third-generation cephalosporin, and recovered and were discharged without sequelae.
Introduction
Extended-spectrum -lactamase (ESBL)-producing Enterobacteriaceae have become a major problem in recent decades especially in nosocomial infections, [1] [2] [3] with a number of outbreaks having been reported worldwide. [4] [5] [6] Several reports have documented the risk of mortality from mis-identification of ESBL producers. 3, 7, 8 In 1999, the NCCLS suggested a new testing and reporting strategy for the identification of ESBL-producing Klebsiella pneumoniae, Klebsiella oxytoca and Escherichia coli. 9 However, this suggestion has only recently been implemented in routine laboratory practice. False reporting may occur as a result of other factors. In K. pneumoniae, two major porins have been implicated in antibiotic resistance. Modification of outer membrane proteins (Omps) OmpK35 (the homologue of OmpF in E. coli) and OmpK36 (the homologue of OmpC in E. coli) combined with production of ESBL have been associated with increased cephalosporin and quinolone MICs. 7, [10] [11] [12] Loss of the porin OmpK36 combined with production of AmpC-like -lactamase has also been described as a cause of increased MICs of carbapenems. 13 In this report, eight outbreak isolates of K. pneumoniae from a neonatal ward were incorrectly designated as ESBL producers due to the loss of an outer membrane protein.
Materials and methods

Patients and bacterial strains
Nine isolates of K. pneumoniae were collected during an outbreak in a neonatal ward from June 1997 to April 1998. Isolates were obtained from eight premature infants with bacteraemia and from one colonized (rectal swab culture) premature infant. All the infants were hospitalized on the day of birth except one who was hospitalized on day 64 after birth. Ceftizoxime or ceftazidime were the main antibiotics used for treatment during and after bacteraemia. All the infants recovered and were discharged.
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Outer membrane protein change combined with co-existing TEM-1 and SHV-1 -lactamases lead to false identification of ESBL-producing Klebsiella pneumoniae 
Confirmatory tests for ESBLs
The double-disc synergy test, Etest for ESBLs and agar diffusion tests were used as screening tests to detect ESBLproducing strains. In the double-disc synergy test, cefotaxime (30 g), ceftazidime (30 g) and aztreonam (30 g) discs were placed on Mueller-Hinton agar adjacent to a co-amoxiclav disc (20 g of amoxicillin plus 10 g of clavulanate). All discs were purchased from Becton Dickinson Microbiology System (Sparks, MD, USA). The procedures and interpretation of the double-disc synergy test were as described previously. 16 The Etest ESBL screen (PDM Epsilometer; AB Biodisk, Solna, Sweden), based on the recognition of a reduction of ceftazidime or cefotaxime MIC in the presence of clavulanic acid, was performed according to the manufacturer's instructions. The agar diffusion test was performed according to NCCLS guidelines. A у5 mm increase in a zone diameter for either ceftazidime/clavulanic acid (30 g/10 g) or cefotaxime/clavulanic acid (30 g/10 g) versus its zone when tested alone was taken as indicative of ESBL production. 
Pulsed-field gel electrophoresis
Total DNA was prepared and pulsed-field gel electrophoresis (PFGE) was performed as described previously. 17, 18 The restriction enzyme XbaI (New England Biolabs, Beverly, MA, USA) was used. Restriction fragments were separated by PFGE in 1% agarose gels (BioRad, Hercules, CA, USA) in 0.5 ϫ TBE buffer (45 mM Tris, 45 mM boric acid, 1.0 mM EDTA, pH 8.0) using a Bio-Rad CHEF-Mapper apparatus (Bio-Rad Laboratories, Richmond, CA, USA). Gels were stained with ethidium bromide and photographed under UV light. Band patterns were compared visually and classified as indistinguishable (clonal), closely related (clonal variants, three or less band differences), possibly related (four to six band differences) and unrelated (more than six band differences) according to criteria described previously. 19 
Transfer of ampicillin resistance by conjugation.
Conjugation was carried out by both broth mating and plate mating. A rifampicin-resistant strain of E. coli (JP-995) was used as the recipient. Recipient and donor strains were separately inoculated into brain-heart infusion (BHI) broth and incubated at 37°C for 4 h. For broth mating, recipient and donor strains were mixed at a volume ratio of 1:1 for overnight incubation at 37°C. The next morning, 0.01 mL of the mixture was spread on a MacConkey agar plate containing rifampicin (100 mg/L) and ampicillin (100 mg/L). As for plate mating, 0.2 mL of the donor and 1.8 mL of the recipient culture were mixed and passed through a filter with a diameter of 2.5 cm and a pore size of 0.45 m. The filter was then placed on a pre-warmed Mueller-Hinton agar plate with the cells uppermost and incubated at 37°C for 4 h. The filter was then immersed in 2 mL of broth and the cells resuspended. A 0.1 mL aliquot of the suspension was then plated on an ampicillin /rifampicin selection plate.
Isoelectric focusing and PCR for bla TEM and bla SHV
Isoelectric focusing (IEF) was performed as described previously. 20 Bacteria were harvested from 20 h BHI broth cultures by centrifugation and the pellet was resuspended in 1 mL of phosphate buffer (0.05 M, pH 7). Enzymes were released by two cycles of freezing (-70°C) and thawing (room temperature), and sonication for 5 min in ice-cold water. IEF was performed in ampholine gel (pH 3.0-10.0; Pharmacia, Uppsala, Sweden). Preparations from standard strains known to harbour TEM-1, SHV-1 and SHV-5 were used as standards. After IEF, -lactamases were detected by spreading nitrocefin (50 mg/L) on the gel surface. For dection of ESBL, molten Mueller-Hinton agar, containing 0.6% (w/v) cefotaxime, 6% (w/v) potassium iodide and 0.6% (w/v) iodine, was poured on to the IEF gel and allowed to solidify. The bands corresponding to ESBLs produced clear halos in the black background of agar within 30 min.
Oligonucleotide primers (Gibco-BRL, Taipei, Taiwan) used for PCR assay were as follows: 5Ј-ATAAAATT-CTTGAAGACGAAA-3Ј (primer A), 5Ј-GACAGTTA-CCAATGCTTAATCA-3Ј (primer B), 5Ј-GGGTAATT-CTTATTTGTCGC-3Ј (primer C) and 5Ј-TTAGCGTT-GCCAGTGCTC-3Ј (primer D). Primers A and B were specific for bla TEM . 21 Primers C and D were specific for bla SHV . 22 Reactions were performed in 50 L mixtures containing 2.5 U Taq polymerase (Promega, Madison, WI, USA), 1 ϫ buffer consisting of 10 mM Tris-HCl pH 8.3, 1.5 mM MgCl 2 , 50 mM KCl, 0.01 g gelatin, 200 M of each deoxynucleoside triphosphate and 2 M of each oligonucleotide primer. Thirty-five cycles were performed for each reaction, with the following temperature profile: 94°C, 1 min; 58°C, 1 min and 72°C, 1 min.
For direct DNA sequencing, PCR products were purified with microspin S-300 HR PCR purification columns (Pharmacia). Sequencing was done with corresponding primers specific for the bla TEM and bla SHV genes 21, 22 according to the method of Sanger et al. 23 An automated sequencer (377, ABI Prism, Perkin-Elmer, CT, USA) was used.
Isolation and analysis of Omp
Bacteria were cultured in Mueller-Hinton broth and low osmolality nutrient broth for 16 h separately. Cell membrane proteins were obtained by disrupting the culture with a VCX 600 sonicator (Sonic and Materials Inc., CT, USA). Cell debris was removed by centrifugation at 6000g for 10 min at 4°C, and the supernatant was subjected to ultracentrifugation at 50 000g for 30 min at 4°C to collect the membranes. Omps were then solubilized in 1.66% sodium lauryl sarcosinate for 30 min at room temperature. The suspension was centrifuged at 5000g for 45 min at 4°C, and the pellet containing the Omp was resuspended in 100 L of double distilled water. The Omps were separated on a SDS-polyacrylamide gel (acrylamide:bisacrylamide ratio 3:0.27; 5% stacking gel; 10% running gel) and were visualized by Coomassie Blue staining (Gibco-BRL).
Results
Genomic fingerprinting
The eight blood culture isolates and one rectal isolate showed identical PFGE patterns (Figure 1 ), indicating that an outbreak of K. pneumoniae infection had occurred in the neonatal ward. (Table) . Initial disc test and MIC results revealed that only cefotaxime met the NCCLS criteria (zone size р27 mm) for further ESBL confirmatory testing among the four indicator antibiotics, aztreonam, ceftazidime, cefotaxime and ceftriaxone. Agar diffusion testing for ESBL production showed significant values (an increased zone size of 5 mm) for cefotaxime/clavulanic acid (30 g/10 g) versus cefotaxime alone. On the other hand, an increase of only 2 mm in the zone diameter (from 29 to 31 mm) was recorded for ceftazidime/clavulanic acid compared with ceftazidime ( Figure 2 ). All tests were repeated twice in two different laboratories to confirm the reproducibility. A phantom phenomenon was observed with cefotaxime Etest strips but not with ceftazidime ( Figure 2 ). According to the manufacturer's recommendations, if either agent gave a positive test result, the isolate should be interpreted as an ESBL producer. Double disc tests showed synergy for all isolates on co-amoxiclav with cefotaxime or ceftriaxone but not with ceftazidime or aztreonam.
Susceptibility testing and confirmatory tests for ESBLs
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Transferability of -lactam resistance and susceptibility testing of transconjugant
The -lactam resistance of isolates was found to be conjugatively transferable. 
IEF, PCR amplification and sequencing of PCR products for bla TEM and bla SHV
IEF of crude extracts identified two -lactamases at pI 5.4 and 7.6, which were similar to TEM-1 and SHV-1 -lactamases, respectively. ESBL detection using a cefotaxime overlay gel failed to show evidence of ESBL activity. All nine K. pneumoniae isolates were positive for both bla TEM and bla SHV amplification. The entire bla TEM and bla SHV sequences including the promoter region for K. pneumoniae were found to be identical to the bla TEM-1 -encoding Tn2 and the published SHV-1 gene sequence. 24, 25 No mutation was found among those strains. No SHV-1 or TEM-1 was detected by PCR amplification in transconjugants. IEF of transconjugants identified one -lactamase corresponding to TEM-1. Insertion sequences between the bla TEM amplification sequences region or gene rearrangement during the conjugation were proved by using new bla TEM -specific primers which were not on the transposon (Tn2) but the structural gene of TEM-1. Positive bla TEM amplification was observed using new primers within the structural gene of TEM-1 (data not shown).
Analysis of Omp
SDS-PAGE analysis of the Omps showed that the clinical isolates and the control strain ATCC 13883 expressed A у5 mm increase in a zone diameter for either antimicrobial agent tested in combination with clavulanic acid versus its zone when tested alone indicates ESBL production. ND, not done; NA, not available.
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OmpK36 but not OmpK35 in Mueller-Hinton broth. Although OmpK35 was highly expressed in control strain ATCC 13883 grown in low osmolality nutrient broth, only extremely low-level expression of OmpK35 was noted in the clinical isolates ( Figure 3 ). This result indicates a deficiency of OmpK35 in the clinical isolates.
Discussion
In the current study, two -lactamases were identified in each of eight outbreak isolates. IEF followed by PCR and sequencing showed that the -lactamases were SHV-1 and TEM-1. No promotor mutation was observed. Recent data suggest that chromosomally encoded SHV-1 in K. pneumoniae produces relatively low levels of enzyme, resulting in moderate resistance to ampicillin. Although previous studies showed that hyperproduction of SHV-1 enzyme is one of the explanations for an increased MIC (2 mg/L) of ceftazidime in K. pneumoniae, 26 the combination of lowlevel production of SHV-1 and normal production of TEM-1 is unlikely to cause an increase in the MIC of cefotaxime. We have tested the susceptibility of two TEM-1-hyperproducing strains of E. coli 27 and one clinical isolate of K. pneumoniae that harboured SHV-1 and TEM-1. Increased MICs of cefotaxime and ceftazidime were not observed as compared with the isolates in this study (data not shown).
Our results suggest that the false designation of isolates as ESBL producers may result from a combination of factors. Several investigators have observed that the loss or reduction of outer membrane proteins in clinical isolates is one of the factors resulting in an increased MIC of ceftazidime. 11, 12, 26, 28 Previous analyses have shown that the major resistance proteins are the outer membrane doublet, OmpK35 and OmpK36. 26, 28 Recently, OmpK37 29 and OmpK45 26, 30 have also appeared to be involved in resistance to -lactam antibiotics. Our results suggest that the combination of low-level expression of OmpK35 and production of SHV-1 and TEM-1 has caused a false designation of ESBL production.
One study showed that OmpF (homologous to OmpK35) is a wider channel than OmpC (homologous to OmpK36), theoretically allowing larger molecules to pass through the outer membrane. 31 Lack of OmpF should presumably play a more important role in resistance than lack of OmpC. However, a highly antibiotic-resistant clinical isolate that lacked OmpC but retained OmpF was isolated from a patient during cephalexin therapy. Subsequent in vitro experiments showed that the synthesis of OmpF was strongly repressed during growth in media of high osmolality, a repression mimicking that seen in human tissues and body fluid. The authors concluded that as OmpF is strongly repressed by high osmolarity such as that in body fluid, the predominant expression of the OmpC porin should play an important role in drug permeability. 31 This observation is in line with one study showing that alteration of Omps, especially the loss of OmpK35 when OmpK36 is present, can result in an increase in the MIC of cefotaxime to 4 mg/L. 29 Thus, the reduced expression of OmpK35 seen in this study probably makes only a marginal contribution to the slightly increased MIC of cefotaxime because OmpK36 still allows -lactams to pass through the outer membrane. Patients may, therefore, be successfully treated with thirdgeneration cephalosoprins as monotherapy.
Another intriguing finding in the present study was the phantom phenomenon in the Etest and the positive disc augmentation in the agar diffusion test. Possibly the combination of decreased outer membrane permeability and the hydrolytic effect of TEM-1 and SHV-1 -lactamases increased the MIC of cefotaxime slightly. The addition of clavulanic acid inhibited TEM-1 and SHV-1 -lactamase production and the reduction in MIC was due to the inhibition of SHV-1 and TEM-1. This caused the Etest phantom phenomenon and the augmentation of the zone size diameter. Since the loss of outer membrane proteins selectively slowed down the penetration of cefotaxime but not ceftazidime, no significant effect was observed with ceftazidime/clavulanate. However, this hypothesis needs further study.
We conclude that the loss of OmpK35 combined with SHV-1 and TEM-1 -lactamases caused false designations of ESBL-producing K. pneumoniae. Reports of ESBL producers should be studied carefully if inconclusive susceptibility test results are obtained. Screens for ESBL producers should be re-evaluated to avoid such false designations. The results from this study suggest that the loss of OmpK35 is not related to third-generation cephalosporin resistance. 
